Radiofrequency ablation therapy (RFA) is considered to be a reliable alternative to surgical resection for patients with primary and metastatic liver tumors. RFA delivers energy into the tumor through non-insulated needle electrode tips, causing a high-frequency alternating current to flow and resulting in coagulation necrosis of the tumor tissue. Compared to percutaneous ethanol injection (PEI) and microwave coagulation therapy (MCT), RFA can induce a larger and more predictable area of coagulation necrosis. Therefore, this technique may reduce the number of required treatment sessions and shorten the hospital stay. Three different RFA devices are presently available, and their usefulness has been compared. Representative adverse effects of RFA include local pain, intra-abdominal bleeding, pleural complications, and needle tract seeding. Although more studies are required to precisely define the indications and to estimate the long-term effects, RFA is expected to become a major therapeutic technique for the treatment of primary and metastatic liver tumors.
Background
As therapeutic modalities for small liver tumors, local ablative therapies such as percutaneous ethanol injection (PEI), microwave coagulation therapy (MCT), and radiofrequency ablation therapy (RFA) have recently become attractive alternatives to surgical resection because they are both effective and less invasive1-9). RFA is a reliable method that can be used to induce thermally mediated coagulation necrosis of tumor tissues percutaneously or intraoperatively. Early clinical trials have been applied to primary liver tumors, mostly hepatocellular carcinomas (HCCs) 10-5), metastatic liver tumors7, [16] [17] [18] [19] [20] , and cervical intramedullary ependymomas21).
This review outlines the technical considerations of RFA and describes experimental and clinical studies involving the use of RFA in the liver, including a metaanalysis of the effects and complications.
Technical overview Radiofrequency waves of between 460 and 500 kHz are generally used in RFA procedures16, 19, 22) .
The converting radiofrequency waves generate an alternating current that passes from an uninsulated electrode into the surrounding tissues. The alternating current changes the direction of ions in the surrounding tissues. The resulting ionic agitation creates frictional heating , which results in the coagulative necrosis of the surrounding tissues23).
Three kinds of generator systems are presently available12,13). The RITA 500 PA generator system (RITA Medical Systems, Mountain View, CA) consists of an electrode needle, including four expandable hooks, with a thermometer ( Fig. 1A) and an RF generator with a maximum output power of 50 W . The RFA can be performed either percutaneously or intraoperatively24). To increase the antitumor effect of RFA, the combination of RFA and balloon occulusion of the hepatic artery or portal vein has been proposed25-27). The resulting reduction in the blood supply reduces the cooling effect of the blood flow, which is benefical to the hyperthermia that is generated by the RF waves . Therapeutic Effects Histopathologic examinations of surgically resected tumors and animal studies have revealed that sufficient coagulation necrosis of non-tumorous and tumorous tissues can be obtained using RFA28, 29, 33) .
The effect of RFA for the treatment of HCC is equivalent to that for metastatic liver tumors16,17).
To evaluate the therapeutic effects of RFA, imaging methods such as ultrasonography (US), enhanced color and power Doppler US, computed tomography (CT), and magnetic resonance imaging (MRI), and tumor markers such as serum alpha-fetoprotein (AFP) or protein induced by vitamin K absence or antagonists-II (PIVKA-II) have been used. If the treatment is not sufficient, RFA can be repeatedly performed. Follow-up assessment of the response to treatment can also be performed using the above-mentioned imaging methods11-13,16,17,34-36). We have performed RFA for HCC and evaluated the therapeutic effect using CT (Fig. 2)35 ).
Several reports on the use of RFA for the treatment of HCCs and liver metastases have been published. Data derived from studies with a follow-up period of more than 1 year and that describe the rates of local recurrence, recurrence at other sites, and disease-free survival rates are summarized in Fig.   3 . disease-free survival rate was 58.5% for all follow-up periods. Thus, the recurrence rates increased and the rates of disease-free survival decreased according to the length of the follow-up period. The survival rate after RFA for the treatment of small HCC reported by Rossi et al.17 ) was similar to that for patients with small HCC who were treated with PEP).
However, most of the studies, including our own data, were performed using a small number of patients and a short follow-up period. We have performed RFA in 15 patients with HCC and have followed these patients for 6 months. The rates of local and other site recurrence, and disease-free survival rate were 6.7% (1 in 15 patients), 20% (3 in 15 patients), and 73.3% (11 in 15 patients), respectively ( Fig. 3) . In addition to the number of patients and the period of follow-up, different tumor characteristics (location and number), different techniques (cool-tip needle electrode or needle electrode including expandable hooks), and different modalities of approach (percutaneous, intraoperative, or laparoscopic)
were used in these reports on RFA. Most of the studies did not include a control group of patients who were treated with a different technique. Therefore, a randomized control study is needed to clarify the effects of RFA and to determine the therapeutic efficacy of RFA.
Complications
The most common adverse effects of RFA are pain, fever, and an elevation of transaminase levels12, 13, 15) . These effects are generally transient and do not require any specific therapy. Most patients complain of mild to moderate pain at the puncture site or epigastrium during the procedure but the pain can usually be tolerated by analgesics, such as pentazosine.
However, several major complications requiring specialized therapy have been reported, and the incidence of major complications is 5-10% of all patients10- 13, 15, 16, 18, 28, 37, 38) . These complications include pleural effusion, ascites, intraperitoneal bleeding, hemorrhage in the treated tumor, pleurisy, hydropneumothorax, ventricular fibrillation, bleeding from the subcostal wound, jaundice, gastric ulcer, and needle tract seeding. Moreover, Livraghi et al.38) reported that RFA had a higher complication rate than PEI in a prospective randomized trial comparing RFA and PEI. Although RFA appears to be a safe and minimally invasive procedure for the treatment of primary and metastatic liver tumors, the possibility of complications should always be kept in mind.
Conclusion
RFA is thought to be an effective and minimally invasive method for the treatment of small liver tumors less than 3 cm in diameter or liver tumors that can not be resected because of deteriorating liver function1,11,16). RFA is useful in patients where PEI or MCT is also indicated. RFA is superior to PEI and MCT with regard to the predictability of the area of coagulation necrosis, and the ability to create larger areas of coagulation necrosis results in a reduction in the number of treatment sessions and a shortening of the hospital stay1, 12, 13) . Moreover, the survival rate for RFA is similar to that of PEI for small HCCs1,17).
The most frequent complications of RFA are mild or moderate pain at the needle insertion site during RFA, a transient increase in serum transaminase levels, and a transient mild fever 10, 12, 35) .
However, major complications such as pleural effusion, intraperitoneal bleeding, and prolonged fevers have been reported, although these complications were treated conservatively in most cases10, 12, 28, 35) .
Although RFA appears to be an important therapeutic method for liver tumors, further studies must be performed to clarify the indications for achieving an optimal therapeutic effect and avoiding major complications.
